Veradigm Inc. (NASDAQ:MDRX) Receives $11.25 Consensus Target Price from Brokerages

Veradigm Inc. (NASDAQ:MDRX) has received an average rating of “Hold” from the five ratings firms that are covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $11.25.

MDRX has been the topic of a number of recent research reports. Barclays initiated coverage on Veradigm in a research note on Wednesday, January 3rd. They issued an “equal weight” rating and a $11.00 target price on the stock. Royal Bank of Canada lowered their target price on Veradigm from $22.00 to $11.00 and set an “outperform” rating on the stock in a research note on Friday, January 19th. StockNews.com began coverage on Veradigm in a research note on Monday. They issued a “hold” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $10.00 price target (down previously from $15.00) on shares of Veradigm in a research report on Tuesday, March 19th.

Veradigm Stock Down 0.8 %

Shares of Veradigm stock opened at $7.45 on Friday. The business has a fifty day simple moving average of $7.85 and a 200-day simple moving average of $10.19. Veradigm has a 12 month low of $5.01 and a 12 month high of $14.09.

Institutional Trading of Veradigm

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP acquired a new position in shares of Veradigm during the 1st quarter worth about $37,000. TFO Wealth Partners LLC lifted its position in shares of Veradigm by 105,280.0% during the 4th quarter. TFO Wealth Partners LLC now owns 5,269 shares of the software maker’s stock worth $52,000 after purchasing an additional 5,264 shares during the last quarter. Gladius Capital Management LP lifted its position in shares of Veradigm by 135.0% during the 4th quarter. Gladius Capital Management LP now owns 6,245 shares of the software maker’s stock worth $66,000 after purchasing an additional 3,587 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Veradigm by 95.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,310 shares of the software maker’s stock worth $67,000 after purchasing an additional 2,587 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of Veradigm by 27.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 32,691 shares of the software maker’s stock worth $69,000 after purchasing an additional 7,027 shares during the last quarter.

Veradigm Company Profile

Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.